In the pursuit of market outperformance, investors navigate the landscape of stock selection. The right picks can play a pivotal role in enhancing your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $0.36 in the prior trading day, Cara Therapeutics Inc (NASDAQ: CARA) closed at $0.35, down -2.47%. In other words, the price has decreased by -$2.47 from its previous closing price. On the day, 0.65 million shares were traded. CARA stock price reached its highest trading level at $0.3599 during the session, while it also had its lowest trading level at $0.3453.
Ratios:
Our goal is to gain a better understanding of CARA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.20 and its Current Ratio is at 5.38. In the meantime, Its Debt-to-Equity ratio is 1.52 whereas as Long-Term Debt/Eq ratio is at 1.52.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Stifel on June 13, 2024, Downgraded its rating to Hold and sets its target price to $1 from $6 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on May 02 ’24 when Posner Christopher sold 3,936 shares for $0.75 per share. The transaction valued at 2,952 led to the insider holds 176,585 shares of the business.
Terrillion Scott sold 2,753 shares of CARA for $2,285 on Apr 05 ’24. The SEC’Y; CHIEF COMPLIANCE & G.C. now owns 88,247 shares after completing the transaction at $0.83 per share. On Apr 05 ’24, another insider, Goncalves Joana, who serves as the CHIEF MEDICAL OFFICER of the company, sold 2,753 shares for $0.83 each. As a result, the insider received 2,285 and left with 53,365 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CARA now has a Market Capitalization of 19300752 and an Enterprise Value of -4838152. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.12 while its Price-to-Book (P/B) ratio in mrq is 0.64. Its current Enterprise Value per Revenue stands at -0.286 whereas that against EBITDA is 0.04.
Stock Price History:
Over the past 52 weeks, CARA has reached a high of $3.45, while it has fallen to a 52-week low of $0.24. The 50-Day Moving Average of the stock is -23.00%, while the 200-Day Moving Average is calculated to be -54.45%.
Shares Statistics:
The stock has traded on average 899.75K shares per day over the past 3-months and 465140 shares per day over the last 10 days, according to various share statistics. A total of 54.48M shares are outstanding, with a floating share count of 45.58M. Insiders hold about 16.63% of the company’s shares, while institutions hold 40.37% stake in the company. Shares short for CARA as of 1721001600 were 613347 with a Short Ratio of 0.68, compared to 1718323200 on 2272266. Therefore, it implies a Short% of Shares Outstanding of 613347 and a Short% of Float of 1.2999999.
